RS67353B1 - Poboljšana il-6 antitela - Google Patents

Poboljšana il-6 antitela

Info

Publication number
RS67353B1
RS67353B1 RS20251073A RSP20251073A RS67353B1 RS 67353 B1 RS67353 B1 RS 67353B1 RS 20251073 A RS20251073 A RS 20251073A RS P20251073 A RSP20251073 A RS P20251073A RS 67353 B1 RS67353 B1 RS 67353B1
Authority
RS
Serbia
Prior art keywords
antibody
seq
ebi
sequence
igg2
Prior art date
Application number
RS20251073A
Other languages
English (en)
Serbian (sr)
Inventor
Michael March Schmidt
Alison Tisdale
Eric Steven Furfine
Grigorios Zarbis-Papastoitsis
Original Assignee
F Hoffmann La Roche Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche Ltd filed Critical F Hoffmann La Roche Ltd
Publication of RS67353B1 publication Critical patent/RS67353B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
RS20251073A 2014-11-07 2015-11-06 Poboljšana il-6 antitela RS67353B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462077105P 2014-11-07 2014-11-07
US201462087448P 2014-12-04 2014-12-04
US201562247705P 2015-10-28 2015-10-28
EP23189385.0A EP4268843B1 (en) 2014-11-07 2015-11-06 Improved il-6 antibodies

Publications (1)

Publication Number Publication Date
RS67353B1 true RS67353B1 (sr) 2025-11-28

Family

ID=54602042

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20251073A RS67353B1 (sr) 2014-11-07 2015-11-06 Poboljšana il-6 antitela
RS20191447A RS59805B1 (sr) 2014-11-07 2015-11-06 Unapređena il-6 antitela

Family Applications After (1)

Application Number Title Priority Date Filing Date
RS20191447A RS59805B1 (sr) 2014-11-07 2015-11-06 Unapređena il-6 antitela

Country Status (33)

Country Link
US (3) US11142571B2 (enExample)
EP (3) EP4268843B1 (enExample)
JP (1) JP6594438B2 (enExample)
KR (2) KR102636726B1 (enExample)
CN (1) CN107249631B (enExample)
AU (1) AU2015342882B2 (enExample)
CA (1) CA2965689C (enExample)
CL (1) CL2017001135A1 (enExample)
CO (1) CO2017005404A2 (enExample)
CR (1) CR20170231A (enExample)
DK (2) DK4268843T3 (enExample)
EA (1) EA035199B1 (enExample)
ES (2) ES3051832T3 (enExample)
FI (1) FI4268843T3 (enExample)
HR (2) HRP20191945T1 (enExample)
HU (1) HUE046181T2 (enExample)
IL (1) IL251858B (enExample)
LT (1) LT4268843T (enExample)
MA (2) MA51554A (enExample)
MX (2) MX385206B (enExample)
MY (1) MY185114A (enExample)
PE (1) PE20171107A1 (enExample)
PH (1) PH12017500809B1 (enExample)
PL (2) PL4268843T3 (enExample)
PT (2) PT4268843T (enExample)
RS (2) RS67353B1 (enExample)
SA (1) SA517381458B1 (enExample)
SG (2) SG10202103420PA (enExample)
SI (2) SI4268843T1 (enExample)
SM (1) SMT202500415T1 (enExample)
UA (1) UA122673C2 (enExample)
WO (1) WO2016073890A1 (enExample)
ZA (1) ZA201702985B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108137681B (zh) 2015-09-23 2024-06-18 豪夫迈·罗氏有限公司 抗-vegf抗体的优化的变体
CA3012350A1 (en) * 2016-02-23 2017-08-31 Sesen Bio, Inc. Il-6 antagonist formulations and uses thereof
WO2018115003A2 (en) * 2016-12-19 2018-06-28 Glenmark Pharmaceuticals S.A. Novel tnfr agonists and uses thereof
EP3600441A1 (en) 2017-03-22 2020-02-05 Genentech, Inc. Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
AR111249A1 (es) 2017-03-22 2019-06-19 Genentech Inc Composiciones de anticuerpo optimizadas para el tratamiento de trastornos oculares
CN109867723B (zh) * 2017-12-05 2022-06-17 南京金斯瑞生物科技有限公司 抗人il6单克隆抗体及其制备方法和用途
CA3174680A1 (en) 2020-03-13 2021-09-16 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
US11999787B2 (en) 2020-03-24 2024-06-04 Genentech, Inc. Tie2-binding agents and methods of use
EP4228706A1 (en) 2020-10-15 2023-08-23 Genentech, Inc. Hyaluronic acid binding derivatives of versican (vg1) for long acting delivery of therapeutics
CN114525235B (zh) * 2022-02-25 2023-07-14 郑州大学 一种提高人表皮生长因子分泌生产效率的方法
CN115343483B (zh) * 2022-08-12 2024-11-26 苏州邦器生物技术有限公司 一种自身免疫性糖尿病检测用试剂盒及其制备方法
AU2023369998A1 (en) * 2022-10-24 2025-01-23 F. Hoffmann-La Roche Ag Predicting response to il-6 antagonists

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4548990A (en) 1983-08-15 1985-10-22 Ciba-Geigy Corporation Crosslinked, porous polymers for controlled drug delivery
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JPH06508511A (ja) 1990-07-10 1994-09-29 ケンブリッジ　アンティボディー　テクノロジー　リミティド 特異的な結合ペアーの構成員の製造方法
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
DE69233769D1 (de) 1991-03-01 2009-09-24 Dyax Corp Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
FR2734739B1 (fr) 1995-06-01 1997-07-11 Gec Alsthom Stein Ind Dispositif de surveillance d'un broyeur a boulets
TW311927B (enExample) 1995-07-11 1997-08-01 Minnesota Mining & Mfg
EP0795743A3 (en) 1996-03-15 1998-02-25 Japan Tobacco Inc. Method and apparatus for infra-red moisture measurement
US5839430A (en) 1996-04-26 1998-11-24 Cama; Joseph Combination inhaler and peak flow rate meter
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
DK0979281T3 (da) 1997-05-02 2005-11-21 Genentech Inc Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
US6358058B1 (en) 1998-01-30 2002-03-19 1263152 Ontario Inc. Aerosol dispensing inhaler training device
DK1137941T4 (da) 1998-12-10 2014-01-06 Brystol Myers Squibb Company Protein-scaffolds til antistof-mimetika og andre bindingsproteiner
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
JP3523245B1 (ja) 2000-11-30 2004-04-26 メダレックス，インコーポレーテッド ヒト抗体作製用トランスジェニック染色体導入齧歯動物
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
WO2002088171A2 (en) 2001-04-26 2002-11-07 Avidia Research Institute Combinatorial libraries of monomer domains
IL161677A0 (en) 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
MXPA04011004A (es) 2002-05-07 2005-01-25 Control Delivery Sys Inc Procesos para formar un dispositivo de administracion de farmaco.
EP1572103A4 (en) * 2002-11-15 2008-02-13 Centocor Inc ANTI-ANGIOGENIC USES OF IL-6 ANTAGONISTS
SG166768A1 (en) 2003-12-23 2010-12-29 Rinat Neuroscience Corp Agonist anti-trkc antibodies and methods using same
ES2426817T3 (es) 2004-08-04 2013-10-25 Mentrik Biotech, Llc Regiones Fc variantes
AU2005282700A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
CN101346395A (zh) 2005-12-30 2009-01-14 默克专利有限公司 阻止复合有IL-6Rα的IL-6与GP130结合的抗IL-6抗体
WO2007104529A2 (en) 2006-03-13 2007-09-20 Ablynx N.V. Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
DK2021463T3 (en) 2006-05-19 2017-01-16 Alder Biopharmaceuticals Inc Culture method to obtain a cloned population of antigen-specific B cells
KR101741731B1 (ko) * 2007-05-21 2017-05-30 앨더바이오 홀딩스 엘엘씨 Ｉｌ-６에 대한 항체 및 이의 용도
AU2008299885C1 (en) 2007-09-14 2015-06-25 Sanofi Pasteur Biologics, Llc Pharmaceutical compositions containing clostridium difficile toxoids A and B
AU2008330125B2 (en) 2007-11-21 2012-11-22 Amgen Inc. Wise binding antibodies and epitopes
US20100187601A1 (en) 2007-12-12 2010-07-29 Fujio Masuoka Semiconductor device
BRPI0907186A2 (pt) 2008-01-15 2015-07-14 Abbott Gmbh & Co Kg Composições proteicas pulverizadas e métodos para sua produção
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
PL2324930T3 (pl) 2008-09-12 2013-02-28 Kdf Co Ltd Urządzenie wytryskujące wodę
WO2010039750A2 (en) 2008-10-01 2010-04-08 Monsanto Technology Llc Transgenic plants with enhanced agronomic traits
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
CN102224169A (zh) 2008-11-26 2011-10-19 葛兰素集团有限公司 多肽、抗体可变结构域和拮抗剂
JP2012516158A (ja) 2009-01-29 2012-07-19 メディミューン，エルエルシー 延長したインビボ半減期を有するヒト抗ｉｌ−６抗体ならびに腫瘍学、自己免疫疾患、および炎症性疾患の治療におけるそれらの使用
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
PE20130643A1 (es) 2010-07-12 2013-06-07 Covx Technologies Ireland Ltd Conjugados de anticuerpos multifuncionales
EP2872534B1 (en) 2012-07-13 2018-08-08 Roche Glycart AG Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
CN106421782A (zh) 2012-10-25 2017-02-22 米迪缪尼有限公司 稳定的低粘度抗体配制品
HK1211599A1 (en) * 2012-11-08 2016-05-27 Eleven Biotherapeutics, Inc. Il-6 antagonists and uses thereof
EA201690212A8 (ru) 2013-07-12 2016-08-31 Офтотек Корпорейшн Способы лечения или профилактики офтальмологических патологических состояний
WO2016073894A1 (en) 2014-11-07 2016-05-12 Eleven Biotherapeutics, Inc. Therapeutic agents with increased ocular retention

Also Published As

Publication number Publication date
ES2756275T9 (es) 2020-10-29
MX2021008663A (es) 2021-08-19
MX2017005992A (es) 2017-09-15
ES3051832T3 (en) 2025-12-30
HUE046181T2 (hu) 2020-02-28
SA517381458B1 (ar) 2020-07-09
US11142571B2 (en) 2021-10-12
EP3215530B9 (en) 2020-09-09
SG10202103420PA (en) 2021-05-28
PH12017500809B1 (en) 2023-09-20
CA2965689A1 (en) 2016-05-12
KR102770849B1 (ko) 2025-02-20
EP3632931A1 (en) 2020-04-08
CN107249631A (zh) 2017-10-13
EA201791005A1 (ru) 2017-09-29
AU2015342882B2 (en) 2021-05-20
MA62787B1 (fr) 2025-11-28
PH12017500809A1 (en) 2017-10-02
CA2965689C (en) 2022-03-22
EP4268843A2 (en) 2023-11-01
IL251858A0 (en) 2017-06-29
EP3215530A1 (en) 2017-09-13
KR102636726B1 (ko) 2024-02-13
SI3215530T1 (sl) 2020-02-28
NZ731090A (en) 2024-03-22
AU2015342882A1 (en) 2017-05-18
PL3215530T3 (pl) 2020-05-18
BR112017008672A2 (pt) 2018-03-20
MY185114A (en) 2021-04-30
IL251858B (en) 2022-09-01
MX385206B (es) 2025-03-14
US20190194312A1 (en) 2019-06-27
CN107249631B (zh) 2021-11-23
EP3215530B1 (en) 2019-08-21
ES2756275T3 (es) 2020-04-27
EP4268843A3 (en) 2023-12-27
HRP20251312T1 (hr) 2025-12-05
CR20170231A (es) 2017-09-25
DK4268843T3 (da) 2025-11-10
DK3215530T3 (da) 2019-11-25
PT4268843T (pt) 2025-10-31
SG11201703574VA (en) 2017-05-30
EP4268843B1 (en) 2025-09-03
SMT202500415T1 (it) 2026-01-12
HK1244008A1 (en) 2018-07-27
KR20170077196A (ko) 2017-07-05
ZA201702985B (en) 2019-10-30
LT4268843T (lt) 2025-11-25
KR20240023450A (ko) 2024-02-21
EA035199B1 (ru) 2020-05-14
WO2016073890A1 (en) 2016-05-12
US20220169719A1 (en) 2022-06-02
PL4268843T3 (pl) 2025-12-15
HRP20191945T1 (hr) 2020-01-24
MA51554A (fr) 2020-11-18
CO2017005404A2 (es) 2017-10-31
PE20171107A1 (es) 2017-08-07
RS59805B1 (sr) 2020-02-28
SI4268843T1 (sl) 2026-01-30
JP6594438B2 (ja) 2019-10-23
JP2017535285A (ja) 2017-11-30
PT3215530T (pt) 2019-11-21
UA122673C2 (uk) 2020-12-28
CL2017001135A1 (es) 2017-12-15
FI4268843T3 (fi) 2025-11-14
US20250059270A1 (en) 2025-02-20

Similar Documents

Publication Publication Date Title
US11459386B2 (en) IL-6 antagonists and uses thereof
US20250059270A1 (en) Il-6 antibodies
WO2016073894A1 (en) Therapeutic agents with increased ocular retention
HK40027816A (en) Improved il-6 antibodies
HK40102410A (en) Improved il-6 antibodies
HK1244008B (en) Improved il-6 antibodies
BR112017008672B1 (pt) Anticorpo ou fragmento de ligação ao antígeno, seu uso, fab isolado, composição, e vetor